269 related articles for article (PubMed ID: 9871860)
1. The effects of unoprostone isopropyl 0.12% and timolol maleate 0.5% on diurnal intraocular pressure.
Stewart WC; Stewart JA; Kapik BM
J Glaucoma; 1998 Dec; 7(6):388-94. PubMed ID: 9871860
[TBL] [Abstract][Full Text] [Related]
2. Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension.
Sharpe ED; Henry CJ; Mundorf TK; Day DG; Stewart JA; Jenkins JN; Stewart WC
Eye (Lond); 2005 Jan; 19(1):35-40. PubMed ID: 15094733
[TBL] [Abstract][Full Text] [Related]
3. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data.
Nordmann JP; Mertz B; Yannoulis NC; Schwenninger C; Kapik B; Shams N;
Am J Ophthalmol; 2002 Jan; 133(1):1-10. PubMed ID: 11755834
[TBL] [Abstract][Full Text] [Related]
4. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension.
Day DG; Schacknow PN; Wand M; Sharpe ED; Stewart JA; Leech J; Stewart WC
Am J Ophthalmol; 2003 Feb; 135(2):138-43. PubMed ID: 12566015
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the intraocular pressure-lowering effect of 0.5% timolol maleate and the docosanoid derivative of a PGF2 alpha metabolite, 0.12% unoprostone, in subjects with chronic open-angle glaucoma or ocular hypertension.
Nordmann JP; Rouland JF; Mertz BP
Curr Med Res Opin; 1999; 15(2):87-93. PubMed ID: 10494491
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%.
Stewart WC; Stewart JA; Day DG; Jenkins J
Acta Ophthalmol Scand; 2004 Apr; 82(2):161-5. PubMed ID: 15043534
[TBL] [Abstract][Full Text] [Related]
7. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide.
Hommer A; Kapik B; Shams N;
Br J Ophthalmol; 2003 May; 87(5):592-8. PubMed ID: 12714402
[TBL] [Abstract][Full Text] [Related]
8. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
Sonty S; Mundorf TK; Stewart JA; Stewart WC
Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of timolol solution once daily versus timolol gel in treating elevated intraocular pressure.
Stewart WC; Leland TM; Cate EA; Stewart JA
J Glaucoma; 1998 Dec; 7(6):402-7. PubMed ID: 9871862
[TBL] [Abstract][Full Text] [Related]
10. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma.
Holló G; Chiselita D; Petkova N; Cvenkel B; Liehneova I; Izgi B; Berta A; Szaflik J; Turacli E; Stewart WC
Eur J Ophthalmol; 2006; 16(6):816-23. PubMed ID: 17191187
[TBL] [Abstract][Full Text] [Related]
12. [Long-term efficacy and safety of combined topical antiglaucoma therapy--timolol & unoprostone vs. betaxolol & unoprostone].
Ohtake Y; Tanino T; Kimura I; Mashima Y; Oguchi Y
Nippon Ganka Gakkai Zasshi; 2004 Jan; 108(1):23-8. PubMed ID: 14969090
[TBL] [Abstract][Full Text] [Related]
13. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of unoprostone isopropyl as an adjunct to topical beta-blocker in patients with open angle glaucoma: a-6-month study.
Leelachaikul Y; Euswas A
J Med Assoc Thai; 2005 Nov; 88 Suppl 9():S100-4. PubMed ID: 16681060
[TBL] [Abstract][Full Text] [Related]
15. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension.
Susanna R; Giampani J; Borges AS; Vessani RM; Jordao ML
Ophthalmology; 2001 Feb; 108(2):259-63. PubMed ID: 11158796
[TBL] [Abstract][Full Text] [Related]
16. Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%.
McCarey BE; Kapik BM; Kane FE;
Ophthalmology; 2004 Aug; 111(8):1480-8. PubMed ID: 15288975
[TBL] [Abstract][Full Text] [Related]
17. Additive efficacy of unoprostone isopropyl 0.12% (rescula) to latanoprost 0.005%.
Stewart WC; Sharpe ED; Stewart JA; Holmes KT; Latham KE
Am J Ophthalmol; 2001 Mar; 131(3):339-44. PubMed ID: 11239866
[TBL] [Abstract][Full Text] [Related]
18. Comparison of dorzolamide/timolol and latanoprost/timolol fixed combinations on diurnal intraocular pressure control in primary open-angle glaucoma.
Eren MH; Gungel H; Altan C; Pasaoglu IB; Sabanci S
J Ocul Pharmacol Ther; 2012 Aug; 28(4):381-6. PubMed ID: 22320418
[TBL] [Abstract][Full Text] [Related]
19. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
[TBL] [Abstract][Full Text] [Related]
20. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
